Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2018 09:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports on Recent Progress and Announces “EM22” Five-year Goals at J.P. Morgan Healthcare Conference

By the end of 2022, Company expects to have three experimental medicines in early-stage clinical trials and two experimental medicines in or ready for late-stage clinical trials Announces first...
January 03, 2018 08:57 ET | Source: Editas Medicine, Inc.

Editas Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
December 11, 2017 18:00 ET | Source: Editas Medicine, Inc.

Editas Medicine Reports Data Supporting Multiple Approaches to Create Treatments for Sickle Cell Disease and Beta-Thalassemia

CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR...
December 06, 2017 07:00 ET | Source: Editas Medicine, Inc.

Editas Medicine, Inc., Announces Pricing of $50 Million Offering of Common Stock

CAMBRIDGE, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 1,970,000 shares...
December 05, 2017 16:17 ET | Source: Editas Medicine, Inc.

Editas Medicine, Inc., Announces Offering of Common Stock

CAMBRIDGE, Mass., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it intends to offer and sell $50,000,000 of shares of...
November 07, 2017 16:03 ET | Source: Editas Medicine, Inc.

Editas Medicine Announces Third Quarter 2017 Results and Update

CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today reported financial results for the third quarter ended September 30,...
November 03, 2017 08:00 ET | Source: Editas Medicine, Inc.

Editas Medicine to Host Conference Call Discussing Third Quarter 2017 Corporate Update and Results

CAMBRIDGE, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Tuesday,...
October 19, 2017 12:45 ET | Source: Editas Medicine, Inc.

Editas Medicine Demonstrates Dose-Dependent, In Vivo Editing with EDIT-101 in CEP290 Transgenic Mice

CAMBRIDGE, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study in transgenic mice...
October 03, 2017 08:00 ET | Source: Editas Medicine

Editas Medicine to Participate in Investor Conferences in October

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
September 26, 2017 16:01 ET | Source: Editas Medicine

Editas Medicine Receives EMA’s Orphan Medicinal Product Designation for EDIT-101 for the Treatment of LCA10

CAMBRIDGE, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the European Medicines Agency (EMA) granted Orphan...